The Role of Narrowband UV-B Plus Alefacept Combination Therapy in the Treatment of Psoriasis

Efficacy of Psoralen UV‐A therapy vs. Narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review

“…There were no significant differences in the median percentage of reduction in PASI at the end of the evaluation [92.9% (89.9–96.1) on the twice weekly side vs. 94.8 (91.8–96.8) on the thrice weekly side, P = 0.179]. A lower median number of sessions was needed for clearance on the twice weekly side compared with the thrice weekly side with 15 sessions 11–25 vs. 22 17–25 respectively, P < 0.0001). Similarly, the median cumulative UVA dose to obtain clearance was lower with the twice‐weekly regimen [142.5 J/cm 2 (106.1–316) vs. 241.4 (169.7–366.3), P = 0.001].…”

“…Of these, 670 were eliminated by reading the title or the abstract and 74 after reading the article. A total of 29 randomized controlled trials were finally selected 6–34 . The detailed flowchart describing both selection process and reasons for exclusion is displayed in Fig.…”

“…[32][33][34] To increase the power to detect potential differences we combined the results from randomized controlled studies with those extracted from therapeutic trials in which the control arm used PUVA or NB-UVB (Table 1) and from studies evaluating a relevant parameter (initial dose, increments…) ( Table 2). A total of 18 publications concerning NB-UVB, [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23] and eight concerning PUVA were finally included in the analysis. [24][25][26][27][28][29][30][31] Efficacy of NB-UVB in chronic plaque psoriasis…”

“…We first examined the influence of the method used to establish the initial dose on clearance rate: 16 studies used the MED to deter-mine the initial dose of NB-UVB phototherapy, [6][7][8][9][10][11][12][13][14][15]19,20,23,[32][33][34] four used skin type 17,18,21,22 and three studies used a fixed dose of NB-UVB. 11,16,18 Fig.…”

A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2

“…Using a split-body study, alefacept was able to reduce PASI scores by 62%, and the addition of narrowband UVB therapy reduced the scores by 81% (grade A evidence) [10]. However, when the combination was compared to narrowband UVB therapy alone in a separate study, no significant difference was detected in patient response (grade A evidence) [11]. …”